To those getting worked up about a Partnership, don't count your chickens before they hatch. I believe in the Webinar WP stated it was a "collaboration" - which in my mind means a splitting of costs of continuing trials at best. That said, he's also admitted openly (same webinar I believe) that they can't afford phase 3 trials themselves.
Far as I can see, there needs to be a deal with cash money involved to continue. If the phase 3 results are good, and I am hedging that we'll see an increased reduction in viral shedding at 12 months, then this could well happen.
The vaccine simply needs a business case. Efficacy is one, need is the other. Need is there, no one wants herpes. Especially Americans, they are hysterical about it.
"Take a Closer Look", page-194
-
- There are more pages in this discussion • 1,034 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.10 |
Change
-0.810(8.17%) |
Mkt cap ! $192.3M | |||
| Open | High | Low | Value | Volume |
| $9.50 | $9.77 | $9.01 | $212.2K | 22.63K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 298 | $9.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.85 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |